Kathleen Munster

Kathleen Munster serves as the Chief Quality Officer and Senior Vice President of Technical Operations. Ms. Munster has experience in global Fortune 500 companies and biotech/start-ups covering Biologics, Cell & Gene Therapy, Solid Dosage and Drug Products. She previously served as head of Business Initiatives & Operational Excellence and SVP, Enabling Functions (Quality, Facilities, and IT) at 2seventy bio (spin-off from bluebird bio). Her experience includes clinical and commercial manufacturing in site-based and global roles spanning Quality Assurance, Quality Control, IT, Facilities and Supply Chain functions. She has expertise in Health Authority inspection management as well as product approval, launch and supply across large molecule, small molecule and cell/gene therapy products. Ms. Munster was also responsible for a global network of sites as VP, Biologics, Cell & Gene Therapy Quality at Catalent Pharma Solutions. Before this, she held a number of leadership roles at Bristol-Myers Squibb including roles of increasing responsibility in Quality, Supply Chain and IT. Ms. Munster started her career at Merck & Co., Inc. and holds degrees in Chemistry and German from Lafayette College and an MBA from Rutgers University.